Howe & Rusling’s AIM ImmunoTech AIM Stock Holding History

Howe & Rusling’s Portfolio AIM Stock Details AIM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-15	Closed	-$2K	–	1208
2022 Q1	$2K	Hold	15	–	–	﹤0.01%	906
2021 Q4	$1K	Hold	15	–	–	﹤0.01%	978
2021 Q3	$3K	Buy	+15	New	+$3.03K	﹤0.01%	825

Other funds holding AIM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Howe & Rusling's AIM Position: Q2 2022 in Review

Howe & Rusling sold out of AIM ImmunoTech (AIM) in Q2 2022, closing a stake of 15 shares — an estimated $2K sold.

Howe & Rusling first reported a position in AIM in Q3 2021 and held it in 3 quarters. The position peaked at $3K in Q3 2021. 36 funds tracked by Wall St. Rank hold AIM as of Q2 2022.

Howe & Rusling reported no remaining AIM ImmunoTech position as of Q2 2022 after selling out during the quarter.
Howe & Rusling sold 15 AIM ImmunoTech shares in Q2 2022, an estimated $2K.
Howe & Rusling first reported a position in AIM ImmunoTech in Q3 2021 and held it in 3 quarters.
Howe & Rusling's AIM ImmunoTech position peaked at $3K in Q3 2021.
36 funds tracked by Wall St. Rank held AIM ImmunoTech as of Q2 2022.

Based on Howe & Rusling's 13F filing for Q2 2022, filed 15 Aug 2022.